Latest From Biocon Ltd.
Yet another valsartan approved as quality/shortage crisis unfolds, while warning letters hit firms on poor root cause investigations and supply chain issues, and FDA investigators procure shirt-button candid cameras.
Keeping Track: Two Goal Date Extensions, Another Herceptin Biosimilar Approval, And A BLA Withdrawal
Indian drug makers are looking in much better shape as US pricing pressures ease and the domestic market regains its double-digit growth, analysts say.
India’s government has hiked healthcare spending in its new budget by 13.5% ahead of national elections, earmarking the lion’s share for its flagship new health insurance scheme for the nation’s poorest half-billion people. But outlays for the stretched core public health-delivery system have stagnated.
- Large Molecule
- Medical Devices
- Therapeutic Areas
- Parent & Subsidiaries
- Biocon Ltd.
- Senior Management
Arun Chandavarkar, PhD, CEO
Siddharth Mittal, CFO
Ravi Limaye, Pres., Mktg.
Narendra Chirmule, PhD, SVP & Head, R&D
- Contact Info
Phone: (91) 80 2808 2808
20th KM Hosur Rd.
Bangalore , 560 100
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.